Cytokinetics Inc CYTK

Healthcare Biotechnology

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

NDAQ:CYTK - Post by User

Cytokinetics Inc

Bullboard Posts

Next >>

Post by AviseAnalyticson Feb 08, 2022 8:58am

131 Views

Post# 34407915

5 BIOTECH STOCKS WITH MAJOR UPCOMING CATALYSTS

$CYTK $ADGI $PHAT $AGIO $ICPT

Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table.

The covered Companies have major upcoming catalysts such as an impending FDA approval, drug launch, data readouts, initiation of clinical trials and IND submission to look forward to.

Learn More:
https://www.aviseanalytics.com/5-biotech-stocks-with-major-upcoming-catalysts/

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant